According to filings with the U.S. Securities and Exchange Commission, Perspective Therapeutics is raising up to $87,409,482.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Johan Spoor played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Perspective Therapeutics
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.

To learn more about Perspective Therapeutics, visit http://www.perspectivetherapeutics.com/

Contact:
Johan Spoor, Chief Executive Officer
206-676-0900

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.